单点唾液样本模型引导精准给药用于耐多药结核左氧氟沙星治疗
该研究在57例口服左氧氟沙星≥7天的成人中采集342对血浆-唾液样本,建立群体药动学模型并评估唾液有限采样策略。结果显示单点2小时唾液浓度可准确预测血浆AUC24,误差在临床可接受范围(<15%),支持用唾液替代血浆进行左氧氟沙星治疗药物监测。
要点
- 单点2小时唾液样本可替代血浆AUC24用于左氧氟沙星TDM
- 三点(0、2、5小时)唾液策略预测误差<15%,临床可接受
- 唾液采样无创,适合血浆TDM困难或伦理受限的场景
核心结论
- 所建popPK模型能利用有限唾液样本可靠估算左氧氟沙星暴露。
- 单点2小时给药后唾液浓度可支持常规耐多药结核治疗中的模型引导TDM。
研究设计与样本
- 前瞻性研究,纳入57例口服左氧氟沙星≥7天的成人患者,共342对血浆-唾液样本。
- 在给药后0、2、5小时同步采集血浆和唾液,用NONMEM建立血浆-唾液群体药动学模型并进行协变量评估。
- 通过贝叶斯估计和蒙特卡洛模拟评估唾液有限采样策略预测血浆AUC24的效能。
主要发现
- 含唾液生物隔室、一级吸收(带滞后时间)和消除的一室模型最佳描述数据。
- 未发现显著协变量。
- 三点唾液策略(0、2、5小时)预测血浆AUC24的误差在临床可接受限内(<15%预测误差)。
- 单点2小时唾液样本的预测准确性与三点策略相当。
- 给药后16小时内的两样本和三样本唾液策略也显示临床可接受的准确性。
临床怎么用
- 在耐多药结核患者中,可考虑用单点2小时唾液浓度替代血浆采样进行左氧氟沙星模型引导TDM。
- 在血浆TDM物流或伦理受限的场景,唾液采样可简化TDM实施。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVES: Levofloxacin is an essential drug in multidrug-resistant tuberculosis (MDR-TB) treatment, but high pharmacokinetic variability necessitates therapeutic drug monitoring (TDM) to optimise exposure and improve outcomes. Traditional TDM requires invasive blood sampling, limiting feasibility. Saliva sampling, a non-invasive matrix may simplify implementation. We aimed to develop a levofloxacin population pharmacokinetic (popPK) model integrating plasma and saliva data, and to evaluate saliva-based limited sampling strategies to support model-informed TDM for levofloxacin in practice. METHODS: Adults receiving oral levofloxacin for ≥ 7 days had plasma and saliva samples collected at 0, 2, and 5 h post-dose. A plasma-and-saliva popPK model was developed using NONMEM, including covariate evaluation. Predictive performance of saliva-based limited sampling strategies for estimating plasma AUC24 was assessed using Bayesian estimation and Monte Carlo simulations. RESULTS: A total of 57 patients with 342 paired plasma-saliva samples were evaluated. One-compartment model incorporating saliva bio-compartment with first-order absorption (with a lag time) and elimination best described the data. No significant covariates were identified. Simulations showed that the three-point saliva strategy (0, 2, 5 h) predicted plasma AUC24 within clinically acceptable limit (< 15% prediction error). A single 2-h sample yielded comparable accuracy. Two- and three-sample saliva strategies up to 16 h post-dose also showed clinically acceptable accuracy. CONCLUSIONS: The developed popPK model enables reliable estimation of levofloxacin exposure from limited saliva samples. A single 2-h post-dose saliva concentration may support model-informed levofloxacin TDM in routine MDR-TB care. This approach may be beneficial in settings where plasma-based TDM is logistically or ethically challenging.
引用
- Nguyen TA, Nguyen TP, Nguyen AT, et al. Single Saliva Sample Model-Informed Precision Dosing of Levofloxacin for Multidrug-Resistant Tuberculosis. Clin Pharmacokinet. 2026. PMID: 41665863. doi:10.1007/s40262-026-01619-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。